Education
About Us
Working with TipRanks
Follow Us
Provexis PLC (GB:PXS)
LSE:PXS
PXS Stock Chart & Stats
0.71p
0.02p(3.46%)
At close: 4:00 PM EST
0.71p
0.02p(3.46%)
Day’s Range― - ―
52-Week Range0.40p - 1.55p
Previous CloseN/A
Volume299.72K
Average Volume (3M)426.62K
Market Cap
£34.25M
Enterprise Value32.32M
Total Cash (Recent Filing)£708.09K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,345,891,400
10 Day Avg. Volume0
30 Day Avg. Volume426,617
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)7.92
Price to Sales (P/S)7.95
P/FCF Ratio-30.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero DebtProvexis's zero total debt materially reduces refinancing and interest-rate risk, improving financial flexibility. This durable balance-sheet strength supports continued investment in commercialisation of Fruitflow®, allows time to build partner revenues, and lowers the probability of distress financing over the next several quarters.
Accelerating Revenue GrowthSharp acceleration in reported revenue indicates growing commercial traction for Fruitflow® and increased partner uptake. As a B2B ingredient supplier, sustained top-line growth off a small base suggests the company can scale revenues with additional partner distribution and product launches, improving the long-term profit potential if margins normalize.
Proprietary Ingredient B2B ModelA proprietary, scientifically supported ingredient sold to third-party manufacturers creates recurring, contractable revenue streams and strong product differentiation. The B2B ingredient model leverages partners' distribution and reduces consumer marketing spend, making growth scalable and defensible if regulatory and scientific credentials remain intact.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flows create ongoing funding risk. Even with improvement versus earlier years, continued cash burn forces reliance on external financing or equity raises, which can dilute shareholders and constrain long-term commercialization investments if partner revenue growth slows or timing lags.
Persistent Losses & Weak MarginsDeep negative margins indicate the current business scale and cost structure are not yet profitable. Without material margin improvement from higher gross margins or operating leverage, earnings recovery will be difficult. Sustained losses raise structural questions about unit economics and long-term viability absent scaling or cost restructuring.
Limited Scale / Small TeamWith only two reported employees and modest equity, Provexis has limited internal resources to manage commercialization, regulatory work, and partner expansion simultaneously. Heavy reliance on third-party partners increases execution risk: failures or delays by partners can materially affect revenue while internal capacity to accelerate alternative routes is constrained.
Provexis News
PXS FAQ
What was Provexis PLC’s price range in the past 12 months?
Provexis PLC lowest share price was 0.40p and its highest was 1.55p in the past 12 months.
What is Provexis PLC’s market cap?
Provexis PLC’s market cap is £34.25M.
When is Provexis PLC’s upcoming earnings report date?
Provexis PLC’s upcoming earnings report date is Sep 25, 2026 which is in 215 days.
How were Provexis PLC’s earnings last quarter?
Currently, no data Available
Is Provexis PLC overvalued?
According to Wall Street analysts Provexis PLC’s price is currently Overvalued.
Does Provexis PLC pay dividends?
Provexis PLC does not currently pay dividends.
What is Provexis PLC’s EPS estimate?
Provexis PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Provexis PLC have?
Provexis PLC has 2,345,891,400 shares outstanding.
What happened to Provexis PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Provexis PLC?
Currently, no hedge funds are holding shares in GB:PXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Provexis PLC
Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.
Technical Analysis
Eco Animal Health
―
Chill Brands Group PLC
―
Mountfield
―
N4 Pharma
―
Shield Therapeutics
―